Protagonist Therapeutics, Inc. $PTGX Shares Bought by Geode Capital Management LLC

Geode Capital Management LLC grew its stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 2.6% during the fourth quarter, Holdings Channel reports. The firm owned 1,452,928 shares of the company’s stock after purchasing an additional 36,282 shares during the period. Geode Capital Management LLC’s holdings in Protagonist Therapeutics were worth $126,920,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in PTGX. Jennison Associates LLC acquired a new position in shares of Protagonist Therapeutics in the 4th quarter valued at $28,924,000. Farallon Capital Management LLC increased its holdings in shares of Protagonist Therapeutics by 0.4% in the 3rd quarter. Farallon Capital Management LLC now owns 6,196,006 shares of the company’s stock valued at $411,601,000 after acquiring an additional 24,000 shares during the period. Mangrove Partners IM LLC increased its holdings in shares of Protagonist Therapeutics by 21.0% in the 3rd quarter. Mangrove Partners IM LLC now owns 478,413 shares of the company’s stock valued at $31,781,000 after acquiring an additional 83,030 shares during the period. GSA Capital Partners LLP purchased a new position in Protagonist Therapeutics in the 3rd quarter valued at $391,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH grew its position in Protagonist Therapeutics by 26.3% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 114,036 shares of the company’s stock valued at $9,960,000 after buying an additional 23,719 shares during the last quarter. Institutional investors and hedge funds own 98.63% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on the stock. Barclays upped their price target on shares of Protagonist Therapeutics from $113.00 to $119.00 and gave the stock an “overweight” rating in a research note on Thursday, March 19th. Wolfe Research assumed coverage on shares of Protagonist Therapeutics in a research note on Thursday, May 21st. They set an “outperform” rating and a $135.00 price target on the stock. Leerink Partners upped their price target on shares of Protagonist Therapeutics from $107.00 to $110.00 and gave the stock an “outperform” rating in a research note on Thursday, March 19th. Jefferies Financial Group reaffirmed a “buy” rating and set a $121.00 price target on shares of Protagonist Therapeutics in a research note on Wednesday, March 18th. Finally, Citigroup reaffirmed an “outperform” rating on shares of Protagonist Therapeutics in a research note on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $115.21.

Insider Buying and Selling at Protagonist Therapeutics

In related news, Director William D. Waddill sold 9,000 shares of Protagonist Therapeutics stock in a transaction on Friday, May 29th. The shares were sold at an average price of $99.64, for a total value of $896,760.00. Following the completion of the sale, the director owned 7,825 shares in the company, valued at approximately $779,683. The trade was a 53.49% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Dinesh V. Ph D. Patel sold 75,000 shares of Protagonist Therapeutics stock in a transaction on Tuesday, May 12th. The stock was sold at an average price of $100.12, for a total transaction of $7,509,000.00. Following the completion of the sale, the chief executive officer owned 523,478 shares of the company’s stock, valued at approximately $52,410,617.36. This trade represents a 12.53% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 263,345 shares of company stock valued at $26,707,266. Corporate insiders own 5.19% of the company’s stock.

Protagonist Therapeutics Stock Performance

NASDAQ PTGX opened at $102.79 on Friday. Protagonist Therapeutics, Inc. has a one year low of $49.38 and a one year high of $107.84. The company’s 50 day moving average price is $101.47 and its 200 day moving average price is $92.45. The firm has a market capitalization of $6.61 billion, a price-to-earnings ratio of -56.79 and a beta of 1.85.

Protagonist Therapeutics (NASDAQ:PTGX) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $0.05 EPS for the quarter, beating the consensus estimate of ($0.50) by $0.55. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. The firm had revenue of $56.37 million for the quarter, compared to analyst estimates of $11.70 million. Sell-side analysts forecast that Protagonist Therapeutics, Inc. will post 3.29 EPS for the current fiscal year.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.